Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older who have been diagnosed with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is abnormally thick and blocks blood flow out of the heart).
- People who have already started taking a medication called mavacamten, or who are planned to start taking it, based on their doctor's medical judgment.
- People whose diagnosis meets recognised international guidelines for this heart condition, including a documented diagnosis and a specific heart measurement (called the LVOT gradient) of 30 mmHg or above, recorded within the past 3 months.
- People whose heart pumping strength (called ejection fraction) has been measured at 55% or higher on a recent heart ultrasound, recorded within the past 3 months.
- People who have moderate-to-significant heart-related symptoms affecting daily activities, classified as NYHA Class II or III, as recorded within the past 3 months.
- People enrolled based on past medical records (retrospectively) must have sufficient baseline medical information and at least one recorded follow-up appointment available in their records.
- People willing to sign a consent form agreeing to take part in the study.
Who may not be able to join:
- People whose heart condition is caused by another underlying disease, such as Fabry disease or amyloidosis, rather than typical hypertrophic cardiomyopathy.
- People who are expected to have major heart surgery during the course of the study.
- People who had a procedure to reduce the thickness of the heart wall (such as surgical removal, alcohol injection, or radiofrequency ablation) within the 6 months before joining the study.
- People who have taken certain heart medications called disopyramide or ranolazine within the 14 days before joining, or who are expected to take disopyramide, ranolazine, or certain combinations of heart medications (verapamil or diltiazem together with beta-blockers) during the study.
- People who have another health condition that, in their doctor's opinion, may prevent them from completing the full 96 weeks of follow-up.
- People who are taking, or are expected to take, certain medications that strongly affect how mavacamten is processed by the body (specifically, moderate to strong CYP2C19 or CYP3A4 inhibitors or inducers) (confirm with trial site).
- People who are currently taking part in another clinical trial that involves a treatment or intervention.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from baseline in Valsalva left ventricular outflow tract (LVOT) gradient; Change from baseline in resting valsalva left ventricular outflow tract (LVOT) gradient
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.